OR-PCI-SIG
11.1.2022 18:02:13 CET | Business Wire | Press release
PCI-SIG® , the organization responsible for the widely adopted PCI Express® (PCIe® ) standard, today announced the official release of the PCIe 6.0 specification, reaching 64 GT/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005011/en/
PCIe 6.0 Specification Features
- 64 GT/s raw data rate and up to 256 GB/s via x16 configuration
- Pulse Amplitude Modulation with 4 levels (PAM4) signaling and leverages existing PAM4 already available in the industry
- Lightweight Forward Error Correct (FEC) and Cyclic Redundancy Check (CRC) mitigate the bit error rate increase associated with PAM4 signaling
- Flit (flow control unit) based encoding supports PAM4 modulation and enables more than double the bandwidth gain
- Updated Packet layout used in Flit Mode to provide additional functionality and simplify processing
- Maintains backwards compatibility with all previous generations of PCIe technology
PCI Express technology has served as the de facto interconnect of choice for nearly two decades. The PCIe 6.0 specification doubles the bandwidth and power efficiency of the PCIe 5.0 specification (32 GT/s), while providing low latency and reduced bandwidth overhead.
“PCI-SIG is pleased to announce the release of the PCIe 6.0 specification less than three years after the PCIe 5.0 specification,” said Al Yanes, PCI-SIG Chairperson and President. “PCIe 6.0 technology is the cost-effective and scalable interconnect solution that will continue to impact data-intensive markets like data center, artificial intelligence/machine learning, HPC, automotive, IoT, and military/aerospace, while also protecting industry investments by maintaining backwards compatibility with all previous generations of PCIe technology.”
“With the PCI Express SSD market forecasted to grow at a CAGR of 40% to over 800 exabytes by 2025, PCI-SIG continues to meet the future needs of storage applications,” said Greg Wong, Founder and Principal Analyst, Forward Insights. “With the storage industry transitioning to PCIe 4.0 technology and on the cusp of introducing PCIe 5.0 technology, companies will begin adopting PCIe 6.0 technology in their roadmaps to future-proof their products and take advantage of the high bandwidth and low latency that PCI Express technology offers.”
“There is a growing demand for ever-increasing performance in many segments in the data center such as high-performance computing and AI,” said Ashish Nadkarni, Group Vice President, Infrastructure Systems, Platforms and Technologies Group, IDC. “Within three to five years the application landscape will look very different and companies will likely begin updating their roadmaps accordingly. The advancement of an established standard like PCIe 6.0 architecture will serve the industry well in establishing composable infrastructure for performance intensive computing use cases.”
To learn more about PCI-SIG, visit www.pcisig.com . PCI-SIG members can download the full specification here .
Additional Resources
About PCI-SIG
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of over 800 industry-leading member companies. To join PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com .
PCI-SIG, PCI Express, and PCIe are trademarks or registered trademarks of PCI-SIG. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
